You are here

Reversal of Myocardial Infarction by Localized Stimulation

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R42HL112519-02
Agency Tracking Number: R42HL112519
Amount: $984,046.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: NHLBI
Solicitation Number: PA12-089
Solicitation Year: 2013
Award Year: 2014
Award Start Date (Proposal Award Date): 2014-05-19
Award End Date (Contract End Date): 2017-04-30
Small Business Information
1000 CATAWBA ST, STE 160
Columbia, SC 29201-5707
United States
DUNS: 829822415
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (803) 216-3867
Business Contact
Phone: (843) 509-1375
Research Institution
COLUMBIA, SC 29208-0001
United States

 Nonprofit college or university

DESCRIPTION provided by applicant Heart attacks i e myocardial infarction or MI occur in more than million patients annually Advances in pharmacological therapy have dramatically improved survival following the initial MI Consequently the number of patients with previous MI continues to increase and as a result put in jeopardy millions of patients for development of heart failure In these patients with a previous MI despite optimal standard of care a scar can form in the portion of the heart muscle myocardium that was injured from the MI Formation of a myocardial scar following MI is associated with a malignant remodeling process with respect to changes in the structure and shape of the MI region infarct expansion This adverse remodeling after MI can lead to increased morbidity and mortality in these patients Unfortunately there are no current pharmacological therapeutic means to specifically target the myocardial scar as a means to halt and or reverse the adverse remodeling post MI The technology to be advanced in this application directly addresses this unmet medical need by expanding previously performed proof of concept studies whereby localized high frequency stimulation LHFS beneficially altered the course of post MI myocardial remodeling This fast track technology transfer application is intended to move forward the LHFS technology by finalizing the prototype of this technology and then optimizing efficacy of this technology in a preclinical animal model of MI These studies will be undertaken in two phases Phase I optimize electrical stimulation parameters for LHFS using a validated in vitro test bed and Phase II in vivo testing of a selected LHFS device in a preclinical large animal model of MI The outcomes from these combined Phase I Phase II projects will move the LHFS technology to establish readiness for clinical feasibility studies PUBLIC HEALTH RELEVANCE The number of patients with an existing heart attack is anticipated to exceed million by next year Unfortunately there is no current pharmacological therapeutic means to treat the area of the heart muscle that is affected by the heart attack This project will optimize parameters of a newly developed electrical technique to target the heart attack region and establish readiness of this novel technique for implementation in patients

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government